Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer

ASCO 2024

31 May - 4 Jun 2024

Published: 2 Jun 2024

Views: 50

Rating:

Save

Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy

Dr Antonio Cigliola speaks to ecancer at ASCO 2024 about interim results from the SURE-01/02 study.

This study evaluated perioperative sacituzumab govitecan alone or in combination with pembrolizumab for patients with muscle-invasive urothelial bladder cancer.

The primary endpoint of the study was to assess the proportion of ypT0N0 and observed responses showed promising activity from perioperative sacituzumab govitecan.

Related Videos

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Pembrolizumab a promising option for MIUC patients after radical surgery

Dr Andrea Apolo - National Cancer Institute, Bethesda, USA

Pembrolizumab a promising option for MIUC patients after radical surgery ( Dr Andrea Apolo - National Cancer Institute, Bethesda, USA )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG

Dr Roger Li - Moffitt Cancer Center, Tampa, USA

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

SG monotherapy demonstrates a high response rate in PT-ineligible patients with...

Prof Daniel Petrylak - Yale University Cancer Center, New Haven, USA

SG monotherapy demonstrates a high response rate in PT-ineligible patients with mUC who progressed after CPI therapy ( Prof Daniel Petrylak - Yale University Cancer Center, New Haven, USA )

More from ecancer